Lv1
40 积分 2024-04-08 加入
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
4个月前
已完结
Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling
6个月前
已完结
皖公网安备34019202002308
